PredxBio
PredxBio is revolutionizing cancer therapeutics by empowering Pharma to get drugs to market faster and help more patients.
- Stage Product In Market
- Industry Biotechnology
- Location Pittsburgh, PA, USA
- Currency USD
- Founded September 2018
- Employees 9
- Incorporation Type C-corp
- Website predxbio.com
Company Summary
PredxBio is powering next-generation cancer therapeutics with AI-driven spatial biomarkers, which delves into the mechanism of action of drugs and predicts patient outcomes with over 90% accuracy. Over the last 3 years, PredxBio has empowered Pharma companies to accelerate discovery and revolutionize clinical trials across some of the highest mortality cancers and will impact the lives of more than 25 million cancer patients around the world.
Team
-
Chief of AI, COO, & Co-founder
Outside of his role as the cofounder, president and COO of PredxBio, Chakra was a tenured associate professor at the U. of Pittsburgh, where he initiated the research that provided the basis for the Company’s products. He also has corporate experience at the NEC Research Institute and IBM Almaden Research Center. Prior to Majumdar joining the team, Chakra was the CEO for the company.
-
CEO
Prior to joining PredxBio in 2022, Dusty’s experience includes leading strategy and marketing as the CMO at IBM and multiple commercial and technical leadership roles at GE Healthcare, Exact Sciences and 3M over the last three decades. In his tenure at IBM, Dusty oversaw the marketing, commercialization, brand strategy execution and digital initiatives across Healthcare and Life Sciences.
Starting a startup?
Join the world's largest startup network for guidance, tools, and fundraising opportunities.